Early-onset Alzheimer's Disease Phenotypes: Neuropsychology and Neural Networks

NCT03153371 | Completed

• 3 other identifiers: 1RF1AG050967UCLA IRB#16-0004961RF1AG050967-01A1
• Study Type: observational
• Target: 180
• Locations: 1 country
• Sites: 1

Brief Summary

This study attempts to identify two types of AD by using clinical and cognitive tasks and brain imaging. The subtypes of AD are separated into a "typical" group (memory loss) and a "variant" group (language, visuospatial, and other cognitive difficulties). Performance on the clinical tasks and brain imaging will be compared among the young-onset Alzheimer's disease group, a late-onset Alzheimer's disease group, and a control group.

Conditions

Alzheimer Disease, Early Onset; Alzheimer Disease; Alzheimer Disease, Late Onset; Dementia, Alzheimer Type; Logopenic Progressive Aphasia; Primary Progressive Aphasia; Visuospatial/Perceptual Abilities; Posterior Cortical Atrophy; Executive Dysfunction; Corticobasal Degeneration; Ideomotor Apraxia

Keywords

Alzheimer's disease; Young-onset; variant; visuospatial; language; apraxia; control; dementia; memory; MRI; neurology; neuropsychology; brain

Outcome Measures

Primary Outcomes (1)

• Alzheimer's disease Subtype

  Neuropsychological testing results for use in a two-stage multivariate diagnostic method that combines the (weighted) test results in order to best discriminate Type 2 AD and typical AD.

  Performed at baseline

Secondary Outcomes (3)

• Change in overall Neurological profile

  Performed at baseline and 1-year follow-up visit

• Brain atrophy in MRI - Magnetic Resonance Imaging of the brain

  Performed at baseline visit

• Change in overall Neuropsychological profile

  Performed at baseline and 1-year follow-up visit

Study Arms (3)

Early-onset Alzheimer's disease

This group will include 90 patients who have been diagnosed with clinically probable early-onset Alzheimer's disease by the UCLA Neurology Clinic (60 variant phenotypes; 30 typical amnestic).

Alzheimer's disease

This group will include 30 patients who have been diagnosed with clinically probable Alzheimer's disease (typical late-onset AD)

Controls

Healthy age-matched individuals without clinically significant cognitive impairments will be enrolled into this study.

Eligibility Criteria

• Age: 50 Years - 85 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients with a diagnosis of early-onset Alzheimer's disease (EOAD; with a diagnosis before age 65), including early-onset neurodegenerative conditions such as primary progressive aphasia (PPA), other aphasias (logopenic, semantic, and non-fluent), posterior cortical atrophy (PCA), ideomotor limb apraxias, and executive dysfunction.

You may qualify if:

• Meet criteria for AD.
• Meet clinical criteria for either typical amnestic AD or variant phenotypes of early-onset (EOAD, or "Type 2 AD").
• Mild-moderate dementia severity
• Sufficient English fluency to complete neuropsychological testing in English.
• Ability to provide consent for participation, or willingness to provide assent and a legally-authorized representative willing to provide surrogate consent.
• Availability of a caregiver informant for participation

You may not qualify if:

• Complicating medical illnesses.
• Significant primary visual impairments.
• Major psychiatric illness not due to the dementia.
• Confounding medications.
• Score 28/30 or higher on the Folstein Mini-Mental Status Exam.
• Age 40-85 years old
• Able to provide consent for participation and express willingness to participate in one-year follow-up visits.
• Have sufficient English fluency to complete neuropsychological testing in English.
• Complicating medical illnesses.
• Significant primary visual impairments.
• Major psychiatric illness not due to the dementia.
• Confounding medications.

Sponsors & Collaborators

• University of California, Los Angeles: lead
• National Institute on Aging (NIA): collaborator
• University of Southern California: collaborator

Study Sites (1)

UCLA Department of Neurology

Los Angeles, California, 90095, United States

Location

MeSH Terms

Conditions

Alzheimer Disease; Aphasia, Primary Progressive; Corticobasal Degeneration; Apraxia, Ideomotor; Language; Apraxias; Dementia

Condition Hierarchy (Ancestors)

Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Tauopathies; Neurodegenerative Diseases; Neurocognitive Disorders; Mental Disorders; Aphasia; Speech Disorders; Language Disorders; Communication Disorders; Neurobehavioral Manifestations; Neurologic Manifestations; Signs and Symptoms; Pathological Conditions, Signs and Symptoms; Psychomotor Disorders; Communication; Behavior

Study Officials

• Mario F Mendez, MD, PhD

  University of California, Los Angeles

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Professor of Neurology and Psychiatry

Study Record Dates

• First Submitted: April 27, 2017
• First Posted: May 15, 2017
• Study Start: April 4, 2016
• Primary Completion: August 31, 2021
• Study Completion: August 31, 2021
• Last Updated: April 30, 2025

Record last verified: 2025-04

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)